R&D expense · 2015–2025
Ascendis Pharma R&D expense
$343M+3.2% · FY2025
Ascendis Pharma (ASND) reported $343M in R&D expense for fiscal 2025, +3.2% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $343M | +3.2% | Open → |
| FY20242024-12-31 | $332M | −25.7% | Open → |
| FY20232023-12-31 | $447M | +11.8% | Open → |
| FY20222022-12-31 | $400M | +14.2% | Open → |
| FY20212021-12-31 | $350M | +17.4% | Open → |
| FY20202020-12-31 | $298M | +38.9% | Open → |
| FY20192019-12-31 | $215M | +29.5% | Open → |
| FY20182018-12-31 | $166M | +47.3% | Open → |
| FY20172017-12-31 | $113M | +53.9% | Open → |
| FY20162016-12-31 | $73.1M | +62.5% | Open → |
| FY20152015-12-31 | $45.0M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2015–2025 compound annual growth +22.5%
Figures are reported under IFRS in EUR and converted to US dollars at ECB reference rates — fiscal 2025 average 0.885 EUR/$ for income items, year-end 0.851 EUR/$ for balance-sheet items.
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ascendis Pharma R&D expense |url=https://companiesranked.com/en/company/ascendis-pharma/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ascendis Pharma R&D expense. CompaniesRanked. https://companiesranked.com/en/company/ascendis-pharma/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-ascendis-pharma-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Ascendis Pharma R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ascendis-pharma/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001193125-26-046590 · February 11, 2026
{{cite web |title=Ascendis Pharma R&D expense — 20-F (0001193125-26-046590) |url=https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-11}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.